Sunshine Biopharma (SBFM) Depreciation & Amortization (CF) (2015 - 2026)

Sunshine Biopharma has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $76859.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 18.62% year-over-year to $76859.0; the trailing twelve-month figure through Mar 2026 stood at $344136.0 (up 40.06% YoY), and the FY2025 full-year result was $332070.0, up 48.56% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $76859.0, down from $98581.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $98581.0 in Q4 2025, with the low at $789.0 in Q3 2022.
• Historically, Depreciation & Amortization (CF) has averaged $47456.8 across 5 years, with a median of $42618.0 in 2024.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) plunged 75.21% — and 2023, when it soared 4614.83%.
• Sunshine Biopharma's Depreciation & Amortization (CF) stood at $18977.0 in 2022, then jumped by 123.18% to $42353.0 in 2023, then jumped by 54.41% to $65399.0 in 2024, then soared by 50.74% to $98581.0 in 2025, then fell by 22.03% to $76859.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $76859.0 (Q1 2026), $98581.0 (Q4 2025), and $96163.0 (Q3 2025), per Business Quant data.